{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:48:41Z","timestamp":1782316121618,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009879","name":"Regione Emilia-Romagna","doi-asserted-by":"publisher","award":["GPG\/2018\/918"],"award-info":[{"award-number":["GPG\/2018\/918"]}],"id":[{"id":"10.13039\/501100009879","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2016-02363646"],"award-info":[{"award-number":["GR-2016-02363646"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 10670"],"award-info":[{"award-number":["IG 10670"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Resistance to tyrosine kinase inhibitors (TKIs) remains a clinical challenge in Ph-positive variants of chronic myeloid leukemia. We provide mechanistic insights into a previously undisclosed MEK1\/2\/BCR::ABL1\/BCR\/ABL1-driven signaling loop that may determine the efficacy of arsenic trioxide (ATO) in TKI-resistant leukemic patients. We find that activated MEK1\/2 assemble into a pentameric complex with BCR::ABL1, BCR and ABL1 to induce phosphorylation of BCR and BCR::ABL1 at Tyr360 and Tyr177, and ABL1, at Thr735 and Tyr412 residues thus provoking loss of BCR\u2019s tumor-suppression functions, enhanced oncogenic activity of BCR::ABL1, cytoplasmic retention of ABL1 and consequently drug resistance. Coherently, pharmacological blockade of MEK1\/2 induces dissociation of the pentameric MEK1\/2\/BCR::ABL1\/BCR\/ABL1 complex and causes a concurrent BCR\n                    <jats:sup>Y360\/Y177<\/jats:sup>\n                    , BCR::ABL1\n                    <jats:sup>Y360\/Y177<\/jats:sup>\n                    and cytoplasmic ABL1\n                    <jats:sup>Y412\/T735<\/jats:sup>\n                    dephosphorylation thereby provoking the rescue of the BCR\u2019s anti-oncogenic activities, nuclear accumulation of ABL1 with tumor-suppressive functions and consequently, growth inhibition of the leukemic cells and an ATO sensitization via BCR-MYC and ABL1-p73 signaling axes activation. Additionally, the allosteric activation of nuclear ABL1 was consistently found to enhance the anti-leukemic effects of the MEK1\/2 inhibitor Mirdametinib, which when combined with ATO, significantly prolonged the survival of mice bearing BCR::ABL1-T315I-induced leukemia. These findings highlight the therapeutic potential of MEK1\/2-inhibitors\/ATO combination for the treatment of TKI-resistant leukemia.\n                  <\/jats:p>","DOI":"10.1038\/s41375-023-01940-x","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T08:02:33Z","timestamp":1688025753000},"page":"1671-1685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["RETRACTED ARTICLE: MEK1\/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia"],"prefix":"10.1038","volume":"37","author":[{"given":"Laura","family":"Mazzera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Abeltino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guerino","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Jottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4511-9748","authenticated-orcid":false,"given":"Attilio","family":"Corradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Ricca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2578-4409","authenticated-orcid":false,"given":"Federico","family":"Armando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3488-2948","authenticated-orcid":false,"given":"Angelo","family":"Peli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-9906","authenticated-orcid":false,"given":"Anna","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-4210","authenticated-orcid":false,"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Scupoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-1686","authenticated-orcid":false,"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Ripamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-515X","authenticated-orcid":false,"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bonati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Perris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4416-7975","authenticated-orcid":false,"given":"Paolo","family":"Lunghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"1940_CR1","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR::ABL11-targeted therapies. Cancer Cell. 2020;37:530\u201342.","journal-title":"Cancer Cell"},{"key":"1940_CR2","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","volume":"98","author":"FE Nicolini","year":"2013","unstructured":"Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, M\u00fcller MC, Hochhaus A, et al. The BCR::ABL1T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98:1510\u20136.","journal-title":"Haematologica."},{"key":"1940_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:612\u201321.","journal-title":"Lancet Oncol"},{"key":"1940_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36:431\u201343.","journal-title":"Cancer Cell"},{"key":"1940_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2174\/1568009617666171002142659","volume":"18","author":"F Massaro","year":"2018","unstructured":"Massaro F, Molica M, Breccia M. Ponatinib: a review of efficacy and safety. Curr Cancer Drug Targets. 2018;18:847\u201356.","journal-title":"Curr Cancer Drug Targets"},{"key":"1940_CR6","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031\u201341.","journal-title":"Blood."},{"key":"1940_CR7","unstructured":"FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia. 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia."},{"key":"1940_CR8","unstructured":"ClinicalTrials.gov. Study of efficacy and safety of asciminib in combination with imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP). 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03578367."},{"key":"1940_CR9","unstructured":"ClinicalTrials.gov. ABL001 + dasatinib + prednisone in BCR-ABL+ B-ALL or CML. 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03595917."},{"key":"1940_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/cncr.23666","volume":"113","author":"D Jones","year":"2008","unstructured":"Jones D, Thomas D, Yin CC, O\u2019Brien S, Cortes JE, Jabbour E, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR::ABL1 kinase inhibitors. Cancer. 2008;113:985\u201394.","journal-title":"Cancer."},{"key":"1940_CR11","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","volume":"133","author":"MA Sanz","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS, Estey EH, L\u00f6wenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133:1630\u201343.","journal-title":"Blood."},{"key":"1940_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00775-018-1537-9","volume":"23","author":"M Hoonjan","year":"2018","unstructured":"Hoonjan M, Jadhav V, Bhatt P. Arsenic trioxide: insights into its evolution to an anticancer agent. J Biol Inorg Chem. 2018;23:313\u201329.","journal-title":"J Biol Inorg Chem"},{"key":"1940_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood-2003-08-2743","volume":"104","author":"P Lunghi","year":"2004","unstructured":"Lunghi P, Costanzo A, Levrero M, Bonati A. Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells. Blood. 2004;104:519\u201325.","journal-title":"Blood."},{"key":"1940_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/sj.leu.2403585","volume":"19","author":"P Lunghi","year":"2005","unstructured":"Lunghi P, Tabilio A, Lo-Coco F, Pelicci PG, Bonati A. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia. 2005;19:234\u201344.","journal-title":"Leukemia."},{"key":"1940_CR15","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1182\/blood-2005-07-2829","volume":"107","author":"P Lunghi","year":"2006","unstructured":"Lunghi P, Costanzo A, Salvatore L, Noguera N, Mazzera L, Tabilio A, et al. MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood. 2006;107:4549\u201353.","journal-title":"Blood."},{"key":"1940_CR16","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1182\/blood-2007-10-114348","volume":"112","author":"P Lunghi","year":"2008","unstructured":"Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, et al. Targeting MEK\/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood. 2008;112:2450\u201362.","journal-title":"Blood."},{"key":"1940_CR17","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1182\/blood-2015-11-681171","volume":"127","author":"Y Dasgupta","year":"2016","unstructured":"Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, et al. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016;127:2131\u201343.","journal-title":"Blood."},{"key":"1940_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3563","volume":"13","author":"EK Greuber","year":"2013","unstructured":"Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer. 2013;13:559\u201371.","journal-title":"Nat Rev Cancer"},{"key":"1940_CR19","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1128\/MCB.01454-13","volume":"34","author":"JY Wang","year":"2014","unstructured":"Wang JY. The capable ABL: what is its biological function? Mol Cell Biol. 2014;34:1188\u201397.","journal-title":"Mol Cell Biol"},{"key":"1940_CR20","first-page":"7149","volume":"62","author":"P La Ros\u00e9e","year":"2002","unstructured":"La Ros\u00e9e P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the BCR::ABL1 kinase inhibitor PD180970 against clinically relevant BCR::ABL1 isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 2002;62:7149\u201353.","journal-title":"Cancer Res"},{"key":"1940_CR21","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR::ABL1 positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96:1070\u20139.","journal-title":"Blood."},{"key":"1940_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2019.03.005","volume":"35","author":"N Luong-Gardiol","year":"2019","unstructured":"Luong-Gardiol N, Siddiqui I, Pizzitola I, Jeevan-Raj B, Charmoy M, Huang Y, et al. \u03b3-catenin-dependent signals maintain BCR-ABL1+ B cell acute lymphoblastic leukemia. Cancer Cell. 2019;35:649\u201363.e10.","journal-title":"Cancer Cell"},{"key":"1940_CR23","first-page":"728","volume":"60","author":"A Bonati","year":"2000","unstructured":"Bonati A, Carlo-Stella C, Lunghi P, Albertini R, Pinelli S, Migliaccio E, et al. Selective expression and constitutive phosphorylation of SHC proteins [corrected] in the CD34+ fraction of chronic myelogenous leukemias. Cancer Res. 2000;60:728\u201332.","journal-title":"Cancer Res"},{"key":"1940_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1535-6108(04)00082-0","volume":"5","author":"F Hayakawa","year":"2004","unstructured":"Hayakawa F, Privalsky ML. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell. 2004;5:389\u2013401.","journal-title":"Cancer Cell"},{"key":"1940_CR25","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1182\/blood-2005-08-3399","volume":"107","author":"VL Goss","year":"2006","unstructured":"Goss VL, Lee KA, Moritz A, Nardone J, Spek EJ, MacNeill J, et al. A common phosphotyrosine signature for the BCR::ABL1 kinase. Blood. 2006;107:4888\u201397.","journal-title":"Blood."},{"key":"1940_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0065-230X(02)85003-5","volume":"85","author":"AM Pendergast","year":"2002","unstructured":"Pendergast AM. The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res. 2002;85:51\u2013100.","journal-title":"Adv Cancer Res"},{"key":"1940_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1042\/BC20080020","volume":"100","author":"A Sirvent","year":"2008","unstructured":"Sirvent A, Benistant C, Roche S. Cytoplasmic signalling by the ABL1 tyrosine kinase in normal and cancer cells. Biol Cell. 2008;100:617\u201331.","journal-title":"Biol Cell"},{"key":"1940_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/ncb1228","volume":"7","author":"K Yoshida","year":"2005","unstructured":"Yoshida K, Yamaguchi T, Natsume T, Kufe D, Miki Y. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of ABL1 in the apoptotic response to DNA damage. Nat Cell Biol. 2005;7:278\u201385.","journal-title":"Nat Cell Biol"},{"key":"1940_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.chembiol.2010.12.013","volume":"18","author":"J Yang","year":"2011","unstructured":"Yang J, Campobasso N, Biju MP, Fisher K, Pan XQ, Cottom J, et al. Discovery and characterization of a cell-permeable, small molecule ABL1 kinase activator that binds to the myristoyl binding site. Chem Biol. 2011;18:177\u201386.","journal-title":"Chem Biol"},{"key":"1940_CR30","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1128\/MCB.16.3.998","volume":"16","author":"J Liu","year":"1996","unstructured":"Liu J, Wu Y, Ma GZ, Lu D, Haataja L, Heisterkamp N, et al. Inhibition of BCR serine kinase by tyrosine phosphorylation. Mol Cell Biol. 1996;16:998\u20131005.","journal-title":"Mol Cell Biol"},{"key":"1940_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/sj.onc.1201524","volume":"16","author":"Y Wu","year":"1998","unstructured":"Wu Y, Liu J, Arlinghaus RB. Requirement of two specific tyrosine residues for the catalytic activity of BCR serine\/threonine kinase. Oncogene. 1998;16:141\u20136.","journal-title":"Oncogene."},{"key":"1940_CR32","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/sj.onc.1210851","volume":"27","author":"B Perazzona","year":"2008","unstructured":"Perazzona B, Lin H, Sun T, Wang Y, Arlinghaus R. Kinase domain mutants of BCR enhance BCR::ABL1 oncogenic effects. Oncogene. 2008;27:2208\u201314.","journal-title":"Oncogene."},{"key":"1940_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","volume":"75","author":"AM Pendergast","year":"1993","unstructured":"Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, et al. BCR::ABL1-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175\u201385.","journal-title":"Cell"},{"key":"1940_CR34","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0960-9822(03)00090-3","volume":"13","author":"GM Mahon","year":"2003","unstructured":"Mahon GM, Wang Y, Korus M, Kostenko E, Cheng L, Sun T, et al. The c-Myc oncoprotein interacts with BCR. Curr Biol. 2003;13:437\u201341.","journal-title":"Curr Biol"},{"key":"1940_CR35","first-page":"188","volume":"62","author":"C Yu","year":"2002","unstructured":"Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, et al. Pharmacologic mitogen-activated protein\/extracellular signal-regulated kinase kinase\/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in BCR\/Abl-expressing human leukemia cells. Cancer Res. 2002;62:188\u201399.","journal-title":"Cancer Res"},{"key":"1940_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc4000","volume":"15","author":"CJ Caunt","year":"2015","unstructured":"Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015;15:577\u201392.","journal-title":"Nat Rev Cancer"},{"key":"1940_CR37","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-06-4312","volume":"67","author":"S Chu","year":"2007","unstructured":"Chu S, Li L, Singh H, Bhatia R. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Cancer Res. 2007;67:7045\u201353.","journal-title":"Cancer Res"},{"key":"1940_CR38","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1182\/blood.V99.8.2957","volume":"99","author":"Y He","year":"2002","unstructured":"He Y, Wertheim JA, Xu L, Miller JP, Karnell FG, Choi JK, et al. The coiled-coil domain and Tyr177 of BCR are required to induce a murine chronic myelogenous leukemia-like disease by bcr\/abl. Blood. 2002;99:2957\u201368.","journal-title":"Blood."},{"key":"1940_CR39","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/21690","volume":"399","author":"JG Gong","year":"1999","unstructured":"Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999;399:806\u20139.","journal-title":"Nature."},{"key":"1940_CR40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1097-2765(02)00431-8","volume":"9","author":"A Costanzo","year":"2002","unstructured":"Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell. 2002;9:175\u201386.","journal-title":"Mol Cell"},{"key":"1940_CR41","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1158\/1078-0432.CCR-09-1229","volume":"15","author":"P Lunghi","year":"2009","unstructured":"Lunghi P, Costanzo A, Mazzera L, Rizzoli V, Levrero M, Bonati A. The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. Clin Cancer Res. 2009;15:6495\u2013502.","journal-title":"Clin Cancer Res"},{"key":"1940_CR42","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.1158\/0008-5472.CAN-07-0655","volume":"67","author":"AR Amin","year":"2007","unstructured":"Amin AR, Paul RK, Thakur VS, Agarwal ML. A novel role for p73 in the regulation of Akt-Foxo1a-Bim signaling and apoptosis induced by the plant lectin, Concanavalin A. Cancer Res. 2007;67:5617\u201321.","journal-title":"Cancer Res"},{"key":"1940_CR43","doi-asserted-by":"publisher","first-page":"18811","DOI":"10.1074\/jbc.M301010200","volume":"278","author":"R Ley","year":"2003","unstructured":"Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1\/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem. 2003;278:18811\u20136.","journal-title":"J Biol Chem"},{"key":"1940_CR44","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/sj.onc.1201053","volume":"14","author":"G Ma","year":"1997","unstructured":"Ma G, Lu D, Wu Y, Liu J, Arlinghaus RB. BCR phosphorylated on tyrosine 177 binds Grb2. Oncogene. 1997;14:2367\u201372.","journal-title":"Oncogene."},{"key":"1940_CR45","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1182\/blood.V82.4.1257.1257","volume":"82","author":"D Lu","year":"1993","unstructured":"Lu D, Liu J, Campbell M, Guo JQ, Heisterkamp N, Groffen J, et al. Tyrosine phosphorylation of P160 BCR by P210 BCR::ABL1. Blood. 1993;82:1257\u201363.","journal-title":"Blood."},{"key":"1940_CR46","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/sj.onc.1204409","volume":"20","author":"F Lin","year":"2001","unstructured":"Lin F, Monaco G, Sun T, Liu J, Lin H, Stephens C, et al. BCR gene expression blocks BCR::ABL1 induced pathogenicity in a mouse model. Oncogene. 2001;20:1873\u201381.","journal-title":"Oncogene."},{"key":"1940_CR47","doi-asserted-by":"publisher","first-page":"8560","DOI":"10.1038\/sj.onc.1206083","volume":"21","author":"RB Arlinghaus","year":"2002","unstructured":"Arlinghaus RB. BCR: a negative regulator of the BCR::ABL1 oncoprotein in leukemia. Oncogene. 2002;21:8560\u20137.","journal-title":"Oncogene."},{"key":"1940_CR48","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1038\/onc.2017.76","volume":"36","author":"A Jain","year":"2017","unstructured":"Jain A, Tripathi R, Turpin CP, Wang C, Plattner R. Abl kinase regulation by BRAF\/ERK and cooperation with Akt in melanoma. Oncogene. 2017;36:4585\u201396.","journal-title":"Oncogene."},{"key":"1940_CR49","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1158\/0008-5472.CAN-11-0068","volume":"71","author":"A Virgili","year":"2011","unstructured":"Virgili A, Koptyra M, Dasgupta Y, Glodkowska-Mrowka E, Stoklosa T, Nacheva EP, et al. Imatinib sensitivity in BCR::ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele. Cancer Res. 2011;71:5381\u20136.","journal-title":"Cancer Res."},{"key":"1940_CR50","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nbt.2620","volume":"31","author":"M Taipale","year":"2013","unstructured":"Taipale M, Krykbaeva I, Whitesell L, Santagata S, Zhang J, Liu Q, et al. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat Biotechnol. 2013;31:630\u20137.","journal-title":"Nat Biotechnol"},{"key":"1940_CR51","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1158\/1541-7786.MCR-10-0356","volume":"9","author":"M Albajar","year":"2011","unstructured":"Albajar M, G\u00f3mez-Casares MT, Llorca J, Mauleon I, Vaqu\u00e9 JP, Acosta JC, et al. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib. Mol Cancer Res. 2011;9:564\u201376.","journal-title":"Mol Cancer Res"},{"key":"1940_CR52","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/leu.2014.38","volume":"28","author":"A Giannoudis","year":"2014","unstructured":"Giannoudis A, Davies A, Harris RJ, Lucas CM, Pirmohamed M, Clark RE. The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. Leukemia. 2014;28:1360\u20133. https:\/\/doi.org\/10.1038\/leu.2014.38.","journal-title":"Leukemia."},{"key":"1940_CR53","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2019.03.005","volume":"35","author":"N Luong-Gardiol","year":"2019","unstructured":"Luong-Gardiol N, Siddiqui I, Pizzitola I, Jeevan-Raj B, Charmoy M, Huang Y, et al. \u03b3-catenin-dependent signals maintain BCR::ABL11+ B cell acute lymphoblastic leukemia. Cancer Cell. 2019;35:649\u201363.e10.","journal-title":"Cancer Cell"},{"key":"1940_CR54","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/j.celrep.2017.11.022","volume":"21","author":"KR Singleton","year":"2017","unstructured":"Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, et al. Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence. Cell Rep. 2017;21:2796\u2013812.","journal-title":"Cell Rep"},{"key":"1940_CR55","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1101\/gad.836800","volume":"14","author":"R Sears","year":"2000","unstructured":"Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14:2501\u201314.","journal-title":"Genes Dev"},{"key":"1940_CR56","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/17512433.2019.1570847","volume":"12","author":"C Trojaniello","year":"2019","unstructured":"Trojaniello C, Festino L, Vanella V, Ascierto PA. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Expert Rev Clin Pharm. 2019;12:259\u201366.","journal-title":"Expert Rev Clin Pharm"},{"key":"1940_CR57","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323.","journal-title":"N Engl J Med"},{"key":"1940_CR58","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","volume":"39","author":"BD Weiss","year":"2021","unstructured":"Weiss BD, Wolters PL, Plotkin SR, Widemann BC, Tonsgard JH, Blakeley J, et al. NF106: a Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. J Clin Oncol. 2021;39:797\u2013806.","journal-title":"J Clin Oncol"},{"key":"1940_CR59","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867\u201376.","journal-title":"N Engl J Med"},{"key":"1940_CR60","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/bcp.12651","volume":"80","author":"R Rissmann","year":"2015","unstructured":"Rissmann R, Hessel MH, Cohen AF. Vemurafenib\/dabrafenib and trametinib. Br J Clin Pharm. 2015;80:765\u20137.","journal-title":"Br J Clin Pharm"},{"key":"1940_CR61","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40880-018-0290-3","volume":"38","author":"H Fu","year":"2018","unstructured":"Fu H, Gao H, Qi X, Zhao L, Wu D, Bai Y, et al. Aldolase A promotes proliferation and G1\/S transition via the EGFR\/MAPK pathway in non-small cell lung cancer. Cancer Commun. 2018;38:18.","journal-title":"Cancer Commun"}],"updated-by":[{"DOI":"10.1038\/s41375-026-03026-w","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01940-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01940-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01940-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:03:40Z","timestamp":1782313420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01940-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1940"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01940-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"assertion":[{"value":"20 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-026-03026-w","URL":"https:\/\/doi.org\/10.1038\/s41375-026-03026-w","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}